<DOC>
	<DOC>NCT01225549</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.</brief_summary>
	<brief_title>The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1860 years of age Prebronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in FEV1 for the early and ≥ 15% for the late response Positive skin prick test to common aeroallergens Any clinically significant disease or disorder Any clinically relevant abnormal finding at screening examinations Smoker or exsmoker who has stopped smoking &lt; 12 months prior to study start Worsening of asthma or respiratory infection within 6 weeks from visit 1 Allergenspecific immunotherapy within 6 months prior to visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Allergen Challenge</keyword>
	<keyword>Asthma</keyword>
	<keyword>Inhaled selective glucocorticoid receptor agonist (iSEGRA)</keyword>
</DOC>